Although reducing the ART gap is critical, emphasis also needs to be placed on the timing of ART provision so that treatment is initiated within 8 weeks of TB treatment for all HIV-positive TB patients, and within 2 weeks for those with CD4 <50 cells/μL to achieve the mortality reduction benefits of ART. This evidence concerns the gene CD4 and tuberculosis.